Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT04262583 Completed - Heart Failure Clinical Trials

Assessment of adherenCe tO Medical theraРy and Its infLuence on Long-term Outcomes In pAtieNts With Heart Failure

COMPLIANCE
Start date: December 1, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of this prospective cohort study is to assess the adherenсe to medical therapy and its influence on long-term outcomes in patients with chronic heart failure in the outpatient registry

NCT ID: NCT04262544 Completed - Heart Failure Clinical Trials

An Innovative Mobile Health Intervention to Improve Self-care in Patients With Heart Failure

Start date: February 20, 2020
Phase: N/A
Study type: Interventional

Heart failure (HF) is associated with high mortality and hospitalization rates. Prior studies show that adherence to routine HF self-care behaviors reduces the risk of all-cause mortality and HF-related hospitalizations, and improves health related quality of life. However, self-care has generally been found to be poor among HF patients. This study aims to assess the feasibility, acceptance, and efficacy of an innovative, patient-centered intervention (iCardia4HF) that aims to promote adherence to HF self-care and improve patient outcomes through the use of commercially available mobile health technologies.

NCT ID: NCT04261452 Completed - COPD Clinical Trials

Heart Failure Worsens Muscle Strength in COPD

Start date: August 1, 2014
Phase: N/A
Study type: Interventional

The combination of heart failure (HF) and chronic obstructive pulmonary disease (COPD) is highly prevalent, but underdiagnosed and poorly recognized. It has been suggested that the decline in functional capacity is associated with musculoskeletal and systemic changes than primary organ (heart and/or lung) failure. In addition, it is recognized that both diseases have several mechanisms that are responsible for musculoskeletal impairment. However, the association of reduced systemic perfusion with low oxygen content observed in the association of HF and COPD may contribute to the worsening of the components of the muscle impairment cascade. Thus, muscle strength and fatigue may not only be even more altered but may also be the main determinants of functional capacity in patients with coexistence of HF and COPD. Although many studies have evaluated the muscle performance of patients with HF or COPD, the literature did not show data on worsening due to the association of the diseases. Particularities identification of the muscle impairment in the coexistence of HF and COPD is fundamental for the development of rehabilitation strategies, mainly through physical exercise. In this line, the present study tested the hypothesis that the coexistence of HF and COPD could present lower values of strength and greater fatigue. Similarly, the muscle dysfunction degree could strongly correlate with the performance markers of the incremental or functional tests in patients with HF associated with COPD. The study protocol was reviewed and approved by the Institutional Research Board. All subjects gave written informed consent before participating in the study.

NCT ID: NCT04255108 Completed - Cardiac Failure Clinical Trials

Validation of a Sensor for Non-invasive Measurement of Stroke Volume and Cardiac Output

Start date: February 19, 2020
Phase:
Study type: Observational

toSense, Inc. has developed a novel, non-invasive, body-worn sensor -CoVa Patch-that offers an alternative to invasive continuous cardiac output monitoring. To validate this new sensor's measurements of stroke volume and cardiac output, toSense, Inc. will conduct a study that compares its measurement performance to that from a pulmonary artery catheter using the thermodilution method.

NCT ID: NCT04254328 Completed - Heart Failure Clinical Trials

The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure

Start date: September 5, 2019
Phase: N/A
Study type: Interventional

Heart failure is a multisystem syndrome characterized by the body's inability to pump or increase the filling pressures required for pumping the blood needed. Typically it shows objective evidence of dyspnea and fatigue during rest or exercise, or swelling of the ankles and cardiac dysfunction. This leads to great loss of functional status and quality of life. These patients seem to be more difficult to participate in cardiac rehabilitation programs due to their more comorbid, fragile and low functional capacity. It has been shown that inspiratory muscle training, which is a part of cardiac rehabilitation, not only improves lung problems but also increases functional capacity and balance, strength of respiratory and peripheral muscles, and decreases perception of depression and dyspnea in patients. Video games are increasingly being used as an alternative to traditional rehabilitation-based exercises to improve daily activity levels and increase physical fitness in the elderly because of their recreational and motivational effects. Although Nintendo wii fit gives similar results with traditional rehabilitation practices, it causes less energy costs. This suggests that it can be a suitable rehabilitation tool for elderly people with low energy levels. A review showed that video games are safe and feasible in the elderly with heart failure. Participants' balance, cognitive functions, quality of life improved and depressive mood decreased. Video games also make older people to communicate better with other family members. The aim of this study was to investigate the effectiveness of inspiratory muscle training and nintendo wii fit exercise training in elderly patients with heart failure and to compare these practices with each other.

NCT ID: NCT04252404 Completed - Acute Heart Failure Clinical Trials

FranceLEVO - Zimino Registry (FZR)

FZR
Start date: February 3, 2020
Phase:
Study type: Observational

The French National Authority for Health (Haute Autorité de santé) requested a registry study to obtain post-market surveillance data to describe baseline clinical profiles, management and outcome of patients treated with Zimino®. This study is designed to provide real-life data on the use, safety and clinical outcomes of Zimino® in routine clinical practice in France.

NCT ID: NCT04252287 Completed - Heart Failure Clinical Trials

A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

CHIEF-HF
Start date: March 10, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).

NCT ID: NCT04249778 Completed - Heart Failure Clinical Trials

Dapagliflozin at Discharge on Hospital Heart Failure Readmission

Start date: July 29, 2020
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of dapagliflozin treatment in preventing hospital re-admissions, emergency room (ER) visits, urgent clinic visits, and death in patients with and without type 2 diabetes (T2D) after hospital admission for heart failure.

NCT ID: NCT04245605 Completed - Acute Heart Failure Clinical Trials

Invasive Coronary Angiography Early in Ischemic Heart Failure

ICE-HF
Start date: April 1, 2010
Phase:
Study type: Observational

To compare the outcomes of patients with acute heart failure who undergo early coronary angiography vs. usual care

NCT ID: NCT04235062 Completed - Heart Failure Clinical Trials

NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure

NATRIUM-HF
Start date: April 1, 2020
Phase: N/A
Study type: Interventional

NATRIUM-HF is a multicenter, non-randomized, pre-post intervention study designed to assess renal response to intravascular fluid expansion and diuretics after sacubitril/valsartan (Entresto®) in euvolemic heart failure patients with reduced ejection fraction. Approximately 230 eligible patients will attend one visit prior to and visits 2 and 3 months after starting Entresto®. At each visit, the patient's responses to extravascular fluid expansion with Ringer's solution and to a loop diuretic bolus will be measured. Biomarkers measured in blood and urine samples will include natriuretic peptides (NP) B-type NP (BNP) and N-terminal proBNP (NT-proBNP), NP fragments, neprilysin activity and concentration, and other biomarkers related to heart failure.